Trial Profile
A Phase I/II Multi-site Study of Rucaparib and Pembrolizumab Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung Cancer After Initial Therapy With Carboplatin, Pemetrexed, and Pembrolizumab
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 02 Feb 2024
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Rucaparib (Primary) ; Carboplatin; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 14 Feb 2023 Status changed from recruiting to active, no longer recruiting.
- 07 Jun 2022 Trial design presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 28 Apr 2022 According to a Clovis Oncology media release, data from the study will be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.